Articles tagged with: Victrelis
Según un artículo reciente, Victrelis e Incivek, dos nuevos medicamentos para el tratamiento de la hepatitis C, podrían estar disponibles pronto para las personas con VIH y hepatitis C. Los autores recomiendan que, mientras eso sucede, se desarrollen estrategias para optimizar la gestión de la hepatitis C en pacientes con VIH con los tratamientos disponibles en la actualidad.
Según los autores del artículo, los resultados de los primeros estudios clínicos para evaluar la seguridad y la eficacia de los dos nuevos inhibidores de la proteasa de la hepatitis C en …
Congresswoman Lee Introduces Bill To Repeal Certain HIV Criminalization Laws – Representative Barbara Lee from California has introduced legislation that requires state officials nationwide to reevaluate HIV criminalization laws. The proposed legislation also offers incentives for states to repeal or modify laws that criminalize behavior by people with HIV that is legal for HIV-negative individuals or that has been shown scientifically to convey no measurable risk of HIV transmission. Representatives Hansen Clark and John Conyers from Michigan are co-sponsors of the bill. For more information, please see Rep. Lee’s press release or the article in the Michigan Messenger.
Large HIV Prevention Trial For Women Modified Due To Viread Inefficacy – A large trial that is testing the efficacy of Truvada (emtricitabine/tenofovir) pills, Viread (tenofovir) pills, and a Truvada vaginal gel in preventing HIV transmission to women has been modified because of interim results showing that Viread pills are ineffective. Based on the results, women in the Vaginal and Oral Interventions to Control the Epidemic (VOICE) study who were taking Viread will stop taking the drug and will no longer be included in the study. Women taking Truvada pills or the Truvada vaginal gel will continue as planned. For more information, please see the National Institutes of Health press release or the article on the Science Magazine website.
Phase 1 Clinical Trial Shows New HIV Vaccine May Be Highly Effective – Results from a Phase 1 clinical trial of a new preventative HIV vaccine in Spain show that 90 percent of healthy HIV-negative adults who received the vaccine showed an immune response; 85 percent still had an immune response one year after vaccination. This is a much higher percentage than researchers have observed in previous vaccine clinical trials. However, the scientists still have to show that the vaccine actually reduces the risk of contracting HIV. The researchers also plan to test the vaccine as a therapeutic vaccine in people who already have HIV to see if it reduces the severity of infection. For more information, please see the press release from Consejo Superior de Investigaciones Científicas or the articles on the ABC news and Fox news websites.
Clinical Trial To Test Victrelis In People With HIV And Hepatitis C Is Currently Recruiting Participants – A Phase 4 clinical trial that will test the efficacy of Victrelis (boceprevir) in HIV-positive adults with hepatitis C virus compared to HIV-negative adults with hepatitis C is currently recruiting participants. Study participants will receive Victrelis in combination with peginterferon-2b (PegIntron) and ribavirin (Rebetol). Eligible participants must not have taken the antiretrovirals Ziagen (abacavir), zidovudine (Retrovir), didanosine (Videx), stavudine (Zerit), Sustiva (efavirenz), or Intelence (etravirine) within the past six months. Additional medication and health restrictions also apply. For more information, please see the U.S. Clinical Trials Registry.
According to a recent review, the new hepatitis C treatment options Victrelis and Incivek may soon be available for people with HIV and hepatitis C. In the meantime, the authors suggested that strategies be developed to optimize management of hepatitis C in HIV patients with currently available treatment options.
According to the authors of the review, results from the first clinical trials evaluating safety and efficacy of the two new hepatitis C protease inhibitors in people co-infected with HIV and hepatitis C should be available later this year.
However, the …
EMA Approves Victrelis For Hepatitis C In Europe – The European Medicines Agency (EMA), which provides marketing authorization for drugs for the European Union, announced this week the approval of Victrelis (boceprevir) for the treatment of hepatitis C in people who are previously untreated or who failed treatment in the past. Victrelis, marketed by U.S. pharmaceutical company Merck (known as MSD outside the U.S.), was approved for use in combination with the current standard hepatitis C treatment, peginterferon alfa (PegIntron or Pegasys) plus ribavirin (Copegus, Rebetol). Victrelis received approval in the U.S. in May, along with Incivek (telaprevir), a second new hepatitis C treatment in the same drug class. For more information, please see the Merck press release.
Government Creates New Website To Fight Discrimination Against People With HIV – The Department of Justice has created a new website to help fight discrimination against people with HIV and AIDS, which is illegal under the federal Americans with Disabilities Act (ADA). The website provides information about HIV’s coverage under the ADA and instructions on how to file a complaint, as well as information on past legal settlements against companies found guilty of discrimination. The ADA prohibits discrimination against people with disabilities in employment, education, healthcare, and housing, among others. For more information, please see the Department of Justice’s ADA AIDS website.
New Jersey Will Implement Medical Marijuana Program – New Jersey governor Chris Christie announced yesterday that he will lift the suspension on the state’s plans to dispense medical marijuana. The governor last month delayed implementing the law to request assurance from the federal government that it would not prosecute state officials for dispensing the drug. However, despite not receiving such assurances, Governor Christie said yesterday that the state can move forward with its plans. Governors of several states have reassessed medical marijuana laws in light of recent letters from the U.S. government threatening to prosecute state employees under federal drug laws (see related AIDS Beacon news). Marijuana is not legal under federal laws, although several states have legalized it for medicinal use. For more information, please see the article in Bloomberg.
Armenia Lifts HIV Travel Ban – Armenia last week became the latest country to lift its ban restricting people with HIV from entering the country. Namibia, China, South Korea, and the U.S. have all lifted travel bans since 2010, although restrictions remain in 48 countries, territories, or areas worldwide. The United Nations Programme on HIV/AIDS (UNAIDS) praised the move, stating that travel bans are discriminatory and have no health or economic justifications. For more information, please see the UNAIDS press release.
HHS Reduces Premiums And Eases Enrollment Requirements For Pre-Existing Condition Insurance Plans – Starting today, the U.S. Department of Health and Human Services (HHS) will reduce insurance premiums by up to 40 percent for federally-administered Pre-Existing Condition Insurance plans (PCIPs) in 18 states and the District of Columbia. The HHS will also no longer require patients to have a denial letter from an insurance company to enroll. Patients still must be U.S. citizens or legal residents, have been without health insurance for at least six months, and have a letter from a health care provider stating that they have or had a medical condition, disability, or illness. PCIPs are insurance plans for people who have pre-existing conditions, including HIV or AIDS, that have made it difficult or impossible to find private health insurance (see related AIDS Beacon news). For more information, please see the HHS press release or the Healthcare.gov website.
CDC Organizes “HIV/AIDS: 30 Years of Leadership and Lessons” Lecture Series – To commemorate the 30th anniversary of the first official report of AIDS by the Centers for Disease Control (CDC), the CDC has put together a series of lectures on the past, present, and future of HIV and AIDS in the U.S. The lectures will begin on June 10 and go through the month of August. They will be held at different locations throughout Atlanta. The talks will discuss key moments that shaped the development of HIV over the past three decades as well as issues such as HIV testing, prevention, and social issues and activism. In addition, the CDC will be sponsoring an online community that will allow individuals affected by HIV to share their stories and experiences. For more information or the lecture series schedule, please see the CDC website.
EMEA Advisory Committee Recommends Approval For Victrelis In Europe – An advisory committee to the European Medicines Agency (EMEA) has recommended that U.S. pharmaceutical company Merck’s new hepatitis C treatment, Victrelis (boceprevir) be approved for use in combination with the current standard hepatitis C treatment, peginterferon alfa (PegIntron or Pegasys) plus ribavirin (Copegus, Rebetol). The recommendation improves the chances for approval of the drug in Europe; a decision is expected within two to three months. Victrelis was approved in the U.S. earlier this month, along with Incivek (telaprevir), a second new hepatitis C treatment in the same drug class. For more information, please see the Merck press release.